Organovo Holdings, based in San Diego, focuses on developing bioprinted human tissues for inflammatory bowel disease, employing 20 staff since its IPO in 2013. The company utilizes proprietary technology and its Mosaic division for research and development of 3D tissues.
VivoSim Labs (VIVS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, VivoSim Labs's actual EPS was -$2.29, beating the estimate of -$2.57 per share, resulting in a 10.83% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
